Background {#Sec1}
==========

Malaria caused by *Plasmodium vivax* is a significant public health issue and is more prevalent than *Plasmodium falciparum* outside Africa, where *P. falciparum* is the predominant species \[[@CR1]\]. Chloroquine and primaquine remains the first-line treatment for vivax malaria. Resistance to anti-malarial drugs is a major hurdle for malaria control strategies. In *P. falciparum*, decreased susceptibility to all the currently used anti-malarial drugs (amodiaquine, chloroquine, mefloquine, quinine, sulfadoxine-pyrimethamine) and more recently, resistance to artemisinin derivatives \[[@CR2]\] has been observed and is a major concern. Although *P. falciparum* resistance to chloroquine (CQ) was reported in the 1950s, the first case of *P. vivax* resistance to CQ was reported only in 1989 from Papua New Guinea \[[@CR3]\]. The mechanisms of *P. vivax* resistance to anti-malarials, have not been extensively studied due to the non-availability of continuous in vitro culture system. A majority of the reported studies have focused on analysing SNPs in resistant gene markers \[[@CR4]\].

The *P. falciparum* orthologs for CQ-resistant genes, *pvcrt*-*o* and *pvmdr*-*1*, of *P. vivax* have been the main focus in studying the CQ resistance \[[@CR5], [@CR6]\]. A number of mutations in both genes have been reported. Among these, K10 insertion in *pvcrt*-*o* and several specific SNPs in *pvmdr*-*1* have been identified as possible molecular markers of CQ resistance in *P. vivax* \[[@CR6], [@CR7]\]. The Y976F and F1076L, which are non-synonymous amino acid mutations of the *Pvmdr*-1, have been reported to correlate with CQ resistance \[[@CR8]--[@CR10]\]. However, in some studies, no significant associations have been found between these mutations and clinical response of *vivax* malaria to chloroquine \[[@CR5], [@CR11], [@CR12]\]. Further, as in *P. falciparum*, copy number variations in *pvmdr1* has been suggested to be associated with anti-malarial resistance \[[@CR13], [@CR14]\]. The *Pvmdr*-*1* gene amplification has been shown to correlate with susceptibility of *P. vivax* to various anti-malarial drugs \[[@CR10]\]. This amplification leads to decreased susceptibility to mefloquine and increased susceptibility to CQ \[[@CR15]\].

India is one of the countries where 80% of the total malaria cases occur worldwide due to *P. vivax* \[[@CR1]\]. There have been several studies reporting CQ resistance in *P. vivax* resulting in fatal malaria in India \[[@CR16]--[@CR19]\]. Mangaluru is a coastal city in Southern Karnataka state of India that has malarial resurgence since 1990. Mangaluru city and its surrounding region are highly malaria endemic. Despite high endemicity and huge health burden, no systematic epidemiological studies with respect to disease severity, clinical manifestations and drug resistance has been conducted in this region. The major malaria parasite in this region is *P. vivax* (\~ 80%). This study is the first attempt to analyse vivax gene markers implicated in isolates obtained from this region.

Methods {#Sec2}
=======

Sample collection and ethics {#Sec3}
----------------------------

The study was conducted at Wenlock District Hospital, Mangaluru. Written consent from participants were taken and blood samples were collected during the period June 2014 to December 2015. Thick and thin smears obtained by finger prick were prepared on glass slides, stained with Giemsa, and examined under light microscopy. Blood samples were collected on Whatman No. 3MM filter paper, allowed to air-dry, placed individually in plastic bags and stored at − 80 °C until processed. A total of 140 *P. vivax* positive patients (as confirmed by microscopy, RDT and 18srRNA amplification by PCR) were included in this study. The study design was in accordance with the ethical guidelines of Indian Council of Medical Research (ICMR) and the National Institutes of Health, USA. The study protocols were approved by the Institutional review board of Kuvempu University, Shivamogga, Karnataka, India, and Pennsylvania State University College of Medicine, Hershey, PA, USA.

DNA extraction and species confirmation {#Sec4}
---------------------------------------

Genomic DNA was extracted from filter paper spots using Chelex-100 reagents (Chelex^®^-100, Himedia, USA) as described \[[@CR20]\]. Briefly, each filter paper punch was incubated with 0.5% saponin in phosphate buffered saline at 4 °C overnight. The punches were washed with 1× PBS for 30 min, transferred to new tubes containing 5% Chelex-100 and vortexed for 30 s; followed by heating at 99 °C for 15 min and centrifuged at 14 K for 2 min. Supernatant was collected and stored at − 20 °C until used.

*Plasmodium vivax* infection identified by microscopy was confirmed by PCR analysis of 18 s ribosomal RNA of parasites in all samples. One genus-specific *(Plasmodium)* and two species-specific (falciparum and vivax) sets of primers were used for PCR analysis, as described previously \[[@CR21]\].

Amplification of chloroquine resistance associated genes {#Sec5}
--------------------------------------------------------

The *pvcrt*-*o* and *pvmdr*-*1* genes were amplified using primers and reaction conditions as described \[[@CR22], [@CR23]\]. Amplification of target gene fragments were performed by PCR using 30 ng template DNA and Phusion^®^ High-Fidelity DNA Polymerase. The PCR cycle conditions were as follows: initial denaturation at 98 °C for 30 s, 30 cycles of denaturation at 98 °C each for 10 s, annealing at primer-dependent temperature for 30 s, and extension at 72 °C for 1.15 min followed by final extension of 72 °C for 5 min. Optimal annealing temperature was 61 °C for both the genes.

Sequence analysis {#Sec6}
-----------------

The PCR amplified gene products were extracted from gels using Gel Extraction kit (Sigma-Aldrich, St Louis, MO, USA) and the extracted DNA was quantified by nanodrop. Sequencing of genes from each isolate was performed on an ABI Prism 377 DNA Sequencer equipped with semi adaptive version 3.0. Nucleotide sequences were analysed using blast and Bio Edit Sequence Alignment Editor and compared with reference sequences of Gen-Bank accession numbers, AF314649 and AY571984 for *pvcrt*-*o* and *pvmdr*-*1*, respectively. Amplification and sequencing were repeated to confirm that the observed SNP variants were not due to PCR or sequencing errors.

Determination of *pvmdr*-*1* gene copy numbers {#Sec7}
----------------------------------------------

*Pvmdr*-*1* copy number was determined by SYBR green based quantitative PCR using the primers as described \[[@CR15]\]. Amplified products of *pvmdr*-*1* and *pvaldolase* (as internal control) were cloned (InsTAclone PCR Cloning Kit (Thermo Scientific Company, USA) into the vector pTZ57R/T and used as calibrators for the assay. For both the genes, 20 µL reaction contained of 10 µL of SYBR green mix (Bio-Rad Laboratories, USA), 0.125 µM of each primer and 1--10 ng genomic DNA. Amplification included a template denaturation step for 4 min at 95 °C, followed by 38 cycles of 95 °C for 30 s and 60 °C for 30 s and 72 °C for 30 s with fluorescence acquisition at the end of each extension step. Amplification was immediately followed by melting at 65--95 °C with stepwise temperature increase of 0.5 °C with fluorescence acquisition at each temperature transition. The assays were repeated. A copy number of \< 1.6 was considered a single copy, and a copy number of ≥ 1.6 was considered multiple copies.

Results {#Sec8}
=======

Analysis of *pvcrt*-*o* gene polymorphisms {#Sec9}
------------------------------------------

The *pvcrt*-*o* gene from 54 isolates of *P. vivax* from Mangaluru were sequenced. Of the 54 isolates analysed, wild type sequence was observed in 51 isolates (94%) and 3 isolates (5.5%) showed insertion of three bases, AAG, leading to K10 insertion in the first exon when compared with reference *pvcrt*-*o* sequence.

Analysis of *pvmdr* -*1* gene polymorphisms and copy number assessment {#Sec10}
----------------------------------------------------------------------

The *pvmdr*-*1* gene amplified from 85 isolates was sequenced. Seven non-synonymous mutations (I946V, T958M, Y976F, F979S, M980V, Y1028C and F1076L) were observed. Among these, I946V and Y1028C mutations were observed for the first time from this region. Prevalence of the Y976F mutation was found to be 7.1% while F1076L mutation was 54.5%. The most prevalent and dominant (90.6%, n = 77) mutation was T958M (Table [1](#Tab1){ref-type="table"}). The F979S and M980V mutations were observed in one sample (1.2% prevalence) alone. *Pvmdr*-*1* from one isolate had 100% homology with wild type gene sequence.Table 1Non synonymous mutations observed among isolatesNoNon synonymous mutationsIsolates N (%)1T958M77 (90.6)2F979S1 (1.2)3M980V1 (1.2)4F1076L65 (76.5)5I946V1 (1.2)6Y976F6 (7.1)7Y1028C1 (1.2)

Ten different haplotypes of *pvmdr*-*1* were observed including one wild type. Single mutants either 958~M~ or 1076~L~, double mutants 958~M~ 976~F~, 958~M~ 1076~L~ and 976~F~ 1076~L~; triple mutants 958~M~ 976~F~1076~L~, 958~M~ 1028~C~ 1076~L~ and 946~V~ 958~M~ 1076~L~; and quadruple mutants 958~M~ 979~S~ 980~V~ 1076~L~ in different frequencies (Table [2](#Tab2){ref-type="table"}).Table 2Different haplotypes having mutations in *Pvmdr*-*1* geneHaplotypeIsolates number (%)958~M~16 (18.8)1076~L~6 (7)958~M~976~F~3 (3.5)958~M~ 1076~L~53 (62.4)976~F~ 1076~L~1 (1.2)958~M~ 976~F~ 1076~L~2 (2.4)958~M~ 1028~C~ 1076~L~1 (1.2)946~V~ 958~M~ 1076~L~1 (1.2)958~M~ 979~S~ 980~V~ 1076~L~1 (1.2)

*Pvmdr*-*1* copy number assessment {#Sec11}
----------------------------------

The *pvmdr*-*1* copy number was analysed for 60 isolates. Of these, a majority of isolates (68.3%, n = 41) had single gene copy while the remaining (31.6%, n = 19) had more than one, i.e.; two, three or four copies.

Discussion {#Sec12}
==========

This study has identified CQ resistance-associated genotypes of *P. vivax* in the highly malaria endemic area of Mangaluru city and its surrounding regions. Importantly, this is the single study so far to analyse the drug resistance associated SNPs from this region. The identified genotypes include those having SNPs in *pvcrt*-*o* and *pvmdr*-*1*, and also those with copy number variations in *pvmdr*-*1* gene. In case of *pvcrt*-*o*, 5.6% of isolates carried an insertion of three bases, namely AAG, in the first exon. This is the first study from India reporting K10 insertion in *pvcrt*-*o*. Earlier studies from Indonesia and Thailand reported a significant increase in CQ IC~50~ that correlated with K10 insertion and Y976F mutation in *pvcrt*-*o* and *pvmdr*-*1* respectively \[[@CR24]\]. In our study, Y976F mutant was also observed among the isolates analysed with the prevalence rate of 7.1%. The previous clinical studies from India \[[@CR8], [@CR25]\] reported susceptibility towards CQ and the mutant Y976F was not observed in these two studies. The major haplotype in our study was found to be 958~M~ 1076~L~ similar to the studies reported earlier \[[@CR25], [@CR26]\]. This suggest that *P. vivax* isolates from Mangaluru are susceptible to CQ, but the occurrence of both Y976F mutants and K10 insertion though at a low rate may be an indication that chloroquine resistance in this geographical area will surface in near future.

Two novel mutations, I946V and Y1028C are observed in *pvmdr*-*1* at the rate of 1.2% (n = 1). While Y1028C is present in the extracellular loop and the other mutation, I946V is on the transmembrane domain of the *pvmdr*-*1* gene where the other reported T958M mutation is present. T958M mutation is observed in majority of the samples (90.6%) analysed in this study. Since T958M mutation is present in isolates from countries having low to high levels of CQ resistance, T958M appears to be an allelic variant of the wild type and is most likely not associated with CQ resistance \[[@CR9], [@CR12], [@CR27]\]. The other two rare mutations, F979S, M980V, observed in this study were also found in isolates from Nepal \[[@CR28]\]. This similarity in parasite population is may be due to the geographical similarity between India and Nepal. Overall the role of these mutations cannot be determined until they correlate with clinical studies.

Among 60 isolates for which copy number of *pvmdr*-*1* gene was analysed, more than half (68.3%) of the isolates have single copy gene and the remaining 31.6% carried multiple copies. Studies have reported that multiple copies inversely correlate with CQ resistance. So, increased percentage of isolates having single copy suggest decreased susceptibility to CQ. However, in vitro together with clinical phenotypic studies are required to confirm the drug susceptibility in this region. Further, since phenotypic studies have not been well established for *P. vivax*, results presented here on *pvcrt*-*o* and *pvmdr*-*1* markers should serve as the base for future studies, monitoring drug resistance in this region. Also, though K-10 insertion is found less frequent, this calls for attention to conduct regular monitoring for the drug resistance in this region for decisions on drug policy.

Conclusion {#Sec13}
==========

Results of the current study show that, the *pvcrt*-*o* and *pvmdr*-*1* gene variants implicated in *P. vivax* CQ resistance are less frequent in Mangaluru. This frequency is an indicator of low *P. vivax* drug resistance, though reflecting a beginning of the trend. Hence, continuous monitoring of drug resistant markers and therapeutic efficacy studies would be desirable for proper management and administration of anti-malarial drugs.
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